Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY: QGEN )

45.06 +0.24 (+0.54%)
Official Closing Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 173,389
Open 44.86
Bid (Size) 41.62 (2)
Ask (Size) 45.50 (1)
Prev. Close 44.82
Today's Range 44.67 - 45.09
52wk Range 39.03 - 47.44
Shares Outstanding 227,985,334
Dividend Yield 2.93%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
From QIAGEN N.V.
Via Business Wire
QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation
From QIAGEN N.V.
Via Business Wire

Performance

YTD
+3.23%
+3.23%
1 Month
+4.18%
+4.18%
3 Month
+0.45%
+0.45%
6 Month
+9.80%
+9.80%
1 Year
+3.68%
+3.68%

More News

Read More
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
From QIAGEN N.V.
Via Business Wire
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 6, 2024
Via Benzinga
Earnings Preview: Qiagen
Via Benzinga
Where Qiagen Stands With Analysts
Via Benzinga
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Via Benzinga
Topics Stocks
Exposures US Equities
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Via MarketBeat
Analyst Expectations for Qiagen's Future
Via Benzinga
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
Via Benzinga
Exposures Product Safety
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Qiagen Unveils Plan For $1B Shareholder Returns, Major Product Launches
Via Benzinga
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
From Myriad Genetics, Inc.
Via GlobeNewswire
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
Via Benzinga
Topics Stocks
Exposures US Equities
QGEN Stock Earnings: Qiagen Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
Via Benzinga
US Stocks Set To Approach New Week With Caution Ahead Of Fed Meeting, Tech Earnings: Analyst Says 'Buy The Dip' Contingent On This Condition
Via Benzinga
Topics Economy
Exposures Interest Rates
Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion
Via Benzinga
Qiagen's Health Odyssey: Expanding In Riyadh And Partnering In Public Projects
Via Benzinga
Qiagen Has Steady Income And Defensive Growth Potential, Goldman Sachs Upgrades Stock
Via Benzinga
These Companies Helped The German DAX Index Hit Its All-time High
Via Talk Markets
Diagnostic Firm Qiagen's Q3 Earnings: Analyst Says Annual Projections Attainable Despite Macro Trends
Via Benzinga
Earnings Scheduled For October 30, 2023
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.